This article examines the ways in which changes in the treatment environment and in measurement perspectives can affect the evaluation of cost-effectiveness of new medications. In three studies we reexamined data from a clinical trial of haloperidol and clozapine conducted from 1993 to 1996. The results of the studies are as follows:
outcomes, including symptomatology, quality of life, and medication side effects. Because of the increased expense associated with newer treatments, cost assessment has also become an ever more important aspect of the evaluation of innovative treatments for this disorder (Weisbrod et al. 1980; Rosenheck and Leslie 2000) .
Cost-effectiveness analysis, which has been particularly prominent in the evaluation of atypical antipsychotics because they cost 10 to 20 times more than conventional agents, is a principal objective of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Cost-effectiveness analysis attempts to synthesize information on the clinical impact and cost consequences of medications as used in actual practice and, as such, is sensitive to changes in the environment of "real world" practice . Several randomized controlled trials conducted in the early 1990s examined the cost-effectiveness of these medications, especially clozapine, and indicated that they generate savings of sufficient magnitude to offset their greater initial expense, at least in patients who have made extensive use of expensive inpatient services (Rosenheck et al. 1997; Essock et al. 2000) .
Because the specific methods proposed for use in the cost-effectiveness evaluation of the CATIE trials have recently been published (Schneider et al. 2002) , we focus here on three factors that may limit the relevance of these "first generation" cost-effectiveness trials to current circumstances and that will need to be given special consideration in the final interpretation of CATIE data: the broad shift in emphasis from inpatient care to rehabilitation, the emphasis on consumer perspectives, and the increased variability in drug prices.
Schizophrenia is a complex, disabling disorder that affects numerous domains of life. As a result, there has been a growing emphasis in recent years on examining multiple
The mental health systems that treat schizophrenia have changed substantially in recent years. While previous studies evaluated the cost-effectiveness of medications in high-cost inpatients, the pressure to lower health care costs has markedly reduced the use of inpatient care in schizophrenia treatment in recent years, sharply diminishing the potential for inpatient cost savings. For example, a study of the treatment of schizophrenia among privately insured employees and their families showed a decline of $1,923 (23%) in average inpatient costs over just 3 years (1993) (1994) (1995) (1996) (Leslie and Rosenheck 1999) . In the Department of Veterans Affairs (VA) health care system, 58 percent of inpatient psychiatry beds were closed between 1995 and 2001; the number of inpatient episodes declined by 42 percent, and lengths of stay by 52 percent (Rosenheck and Greenberg 2002) . A study of potential savings from the use of atypical antipsychotics in the VA showed that, in 1999, only 26 percent of VA patients diagnosed with schizophrenia were hospitalized at all, and only 7 percent had more than 30 days of hospitalization, the minimum number required for participation in the 1993-1996 VA clozapine cost-effectiveness study . The primary focus of attention in studies of the cost-effectiveness of new antipsychotic medications must thus shift to the use of outpatient and community services, which at least one study has shown to increase with clozapine treatment (Luchins et al. 1998 ).
There has been growing emphasis in recent years on opening the "black box" of interventions (Rossi et al. 1993) to better understand the mechanisms and processes through which they achieve their effects and their relevance to diverse stakeholders and payers. However, no studies to date have examined the clinical processes through which innovative treatments for schizophrenia, and atypical antipsychotics in particular, affect cost. While the majority of studies have found that atypical antipsychotics are associated with reduced extrapyramidal side effects (EPS) (Leucht et al. 1999) , many have also found reductions in symptoms (Kane et al. 1988; Rosenheck et al. 1997) , and a few have found evidence of improved social functioning (Meltzer et al. 1990; Rosenheck et al. 1997; Tollefson and Kuntz 1999) . However, none of these studies examined the relationship of these clinical changes to cost, a set of relationships that might help planners anticipate the effects of more effective antipsychotic medications, including those yet to be developed, on specific components of cost. Of particular interest is the impact of more effective medication on outpatient, community, and rehabilitation components of mental health care, components of increasing importance as reliance on inpatient services declines.
Second, the first generation cost-effectiveness studies of atypical antipsychotics evaluated the effectiveness of treatment using standardized rater-based measures with well-demonstrated psychometric properties. However, increasing emphasis has been placed in recent years on consumers' assessments of the value of their treatment. Only one study has compared rater-based and client-based outcome assessments; it found that quality of life improved on standard instruments, but not from the perspective of subjective consumer judgment (Cramer et al. 2000) . However, that study focused on only one outcome domain. It is becoming increasingly important to assess a broad range of factors and responses that affect subjective experiences and to consider overall assessment of all aspects of treatment value from the perspective of consumers.
Finally, recent studies have also increased awareness of previously unaddressed variation in drug prices-both between medications, as a greater variety of products are brought to market, and between health care systems, some of which have been able to use their market power to negotiate reduced prices (U.S. General Accounting Office 2000; , and commercial vendors operating in an increasingly competitive retail pharmacy market.
This study seeks to examine the potential consequences of recent changes in the treatment environment and the broadening of perspectives from which the costeffectiveness of new antipsychotic medications must be considered, through a series of secondary analyses of data from a randomized clinical trial comparing clozapine and haloperidol that was conducted in the VA system between 1993 and 1996. First, we attempt to identify the influence of three clinical intermediates-psychotic symptoms, social functioning, and EPS-on the relationship of clozapine to costs. Structural equation modeling is used to model the sequential impact of clinical mediators on various subcomponents of total societal costs and particularly on inpatient and outpatient costs. Structural equation modeling is an extension of multiple regression analysis (Hayduk 1987) in which each variable is analyzed as having both direct effects on the final outcome and indirect effects through its influence on temporally intermediate variables.
In a world in which the potential for inpatient savings is decreasing, it is important to know how clinical changes differentially affect the components of total cost.
Second, we will examine a broader range of assessments from the same trial that will allow evaluation of treatment from the perspectives of providers and patients-key stakeholders whose judgments have not been addressed in previous publications.
Finally, we will compare drug costs in the 1993-1996 trial with the far more variable drug costs of today, across agents, service systems, and commercial vendors. We thus seek to reexamine data from a pioneering older study to identify a series of factors that may complicate our assessment of the cost-effectiveness of new antipsychotic medications in the CATIE trials and in studies that will evaluate pharmacological agents as they are released in the years to come.
Methods
Subjects. In the original VA study, patients meeting criteria for refractory schizophrenia (n = 423) at 15 VA medical centers were randomly assigned (during a 24-month recruitment period) to clozapine or haloperidol and treated for 12 months. Eligibility was restricted to patients who both were currently hospitalized and had a history of high inpatient health service use, denned as between 30 days' and 364 days' hospitalization for schizophrenia during the previous 12 months. Odier criteria, described in detail elsewhere (Rosenheck et al. 1997) , included (1) DSM-III-R diagnosis of schizophrenia, as evidenced by the Semi-Structured Clinical Interview for Diagnosis (Spitzer and Endicott 1990) ; (2) refractoriness, defined as persisting psychotic symptoms despite two adequate trials of alternative drug treatments; (3) severe symptoms, as evidenced by above-threshold scores on the Brief Psychiatric Rating Scale (Overall and Gorham 1962 ) and the Clinical Global Impressions Scale (Guy et al. 1916b) ; and (4) significant social dysfunction for the previous 24 mondis. Exclusion criteria included an inability to give informed consent, a previous trial of clozapine, a current myeloproliferative disorder, or pregnancy.
Patients were interviewed at baseline and followed up at 6 weeks, and 3, 6, 9, and 12 months. Only baseline and 6-month interview data were used in this analysis, and only 317 patients had complete data at both of these time points.
Treatment
Pharmacotherapy. Following entry into the study and initial assessment, patients were randomly assigned to pharmacological treatment with either clozapine (100-900 mg/day) or haloperidol (5-30 mg/day), within centers. Dose adjustments were made as required, using 12 fixed dose levels. Patients receiving haloperidol were also administered benztropine mesylate (2-10 mg/day) to counteract EPS, while those receiving clozapine were given a matching benztropine placebo. To maintain the blinding, patients in the haloperidol group also received weekly blood counts, as is indicated for clozapine treatment.
Psychosocial treatment. A predefined set of psychotherapeutic and rehabilitative treatments were offered through a "broker-advocate" case management model, the details of which have been discussed elsewhere (Rosenheck et al. 1998) , implemented uniformly at each center. This model consisted of a 15-minute weekly meeting between patient and case manager that focused on patient readiness for and interest in participating in various psychosocial treatments. Continuation of previous psychosocial treatments was permitted, but only 20 percent of the clozapine group and 17 percent of the haloperidol group (a nonsignificant difference) were involved in such treatments at baseline. Treatment was based on clinical need and patient interest, both of which were systematically documented (Rosenheck et al. 1998 ).
Standardized outcomes assessments. Symptoms
were assessed with the Positive and Negative Syndrome Scale (PANSS) for schizophrenia (Kay et al. 1987) . Social functioning was evaluated with the Heinrichs-Carpenter Quality of Life Scale (QOLS) (Heinrichs et al. 1984) . EPS were assessed using the Simpson-Angus Scale (Simpson and Angus 1970) , along with the Barnes Akathisia Scale (Barnes 1989 ) and the Abnormal Involuntary Movement Scale for tardive dyskinesia (Guy 1976a) . Because the Simpson-Angus Scale represented the broadest range of EPS, it was selected as representative of EPS for the analyses presented in uiis article.
Supplementary outcome measures. In addition to these standard measures, outcomes were assessed more specifically from the perspective of providers and patients.
Provider judgments of improvement were assessed in two ways. First, at each visit providers were asked to assess the degree of clinical improvement from baseline on a five-point scale (0 = much worse, 1 = worse, 2 = no change, 3 = better, 4 = much better). In addition, at the end of the trial, providers were asked to identify which patients had shown "dramatic improvement" over the course of die trial.
Patients' personal assessments of their status and response to medication were also assessed in several ways. First, at each assessment point they were asked to rate tiieir overall quality of life on a seven-point scale from 1 (terrible) to 7 (delighted) (Lehman 1988) . Second, patients responded to five yes-no questions about their experience on tiieir medication. These questions asked (1) whether die medication made them feel weird or like a "zombie," (2) whether they believed medication could help prevent their getting sick, (3) whedier they felt more normal on medication, (4) whether their medication had helped them, and (5) whether other people thought their medication had helped them. These dichotomous items were examined individually and averaged together to form a subjective medication effectiveness scale (Cronbach's alpha, 0.60).
Second, patients were asked about their personal assessment of their adherence to the medication regimes on a scale from 1 (never missed taking the medication) through 5 (stopped taking die medication altogedier).
Finally, patients were asked about the presence of seven common antipsychotic side effects: tachycardia, hypotension, salivation, weight gain, sedation, EPS, and restlessness (akathisia). For each side effect they were asked whether it was present, whether they attributed it to the study drug (0 = no, 1 = possible, 2 = probable), and how severe it was (1 = mild, 2 = moderate, 3 = severe).
Cost assessment A detailed description of the methods by which costs were calculated has been published elsewhere . The methods will be summarized briefly here.
Costs were estimated by multiplying the number of units of service provided to each patient by estimated unit costs for each facility. VA health service utilization data were derived from the VA's national computerized workload systems. Unit costs for VA general psychiatry and substance abuse inpatient and outpatient care (including group treatment and day hospital care) were estimated for each medical center, using cost data from the local Cost Distribution Report (CDR) and computerized workload data (Rosenheck et al. 1995) . Costs of VA medical, surgical, domiciliary, and nursing home care and of the various types of non-mental health outpatient treatment were estimated using national average CDR costs. Because this was a national multisite study, costs were adjusted for differences in locality pay.
Use of non-VA services was evaluated through patient interviews, and data on non-VA unit costs were based on a previous study that compared VA with non-VA costs in numerous communities (Office of the Inspector General 1992).
The costs of pharmacological agents were based on 1995 VA pharmacy cost levels ($2.13/100 mg for clozapine; $0.02/5 mg for haloperidol). The expense incurred by blood draws, white blood cell counts, and additional pharmacy processing was incorporated into the cost of treatment ($14/week for clozapine).
Interview data were used to estimate usage of non-health care services. The costs of these services were derived from interview data and published literature. These costs included criminal justice system costs (because of arrests and incarceration) (Department of Justice, Office of Justice Programs 1991a, 1991 b), productivity (based on earnings from employment, a negative cost), family burden (days lost by family members from work and from unpaid domestic activity as a result of caring for the patient, valued at twice the minimum wage) (Tessler and Gamache 1994) , and the administrative costs of transfer payments (i.e., income from programs that provide public support, such as welfare and disability payments). For transfer payments, only administrative costs were included, because only they represent additional consumption of total societal (as contrasted with governmental or taxpayer) resources (Frisman and Rosenheck 1996) . Data on inpatient costs, outpatient costs, total health care costs, non-health care costs, and societal costs were thus available and analyzed for the 6 months prior to study entry and for the second 6 months of the study (i.e., months 6-12 after initial randomization).
Statistical analysis. Because the statistical program for structural equation modeling requires complete data on all subjects, only the subset of patients for whom such data are available were included in the analyses (n = 317). A preliminary analysis thus compared the subset of patients on whom complete data were available to those for whom complete data were not available. Although our goal was to conduct an intention-to-treat analysis of all subjects as randomized, because this subsample of the patients did not include subjects with missing data we compared those assigned to clozapine and haloperidol to identify any potential variables that might bias subsequent analyses. Group differences in demographic variables at baseline were assessed using either Student t test (continuous measures) or chi-square test (categorical measures).
Structural equation modeling was then utilized to evaluate the relationship of clozapine treatment to clinical status at 6 months, and the relationship of 6-month clinical status to the various components of costs during the 6-to 12-month period. The direct effects between clozapine and health care costs, and between baseline health status and 6-month health status, were also modeled, along with the relationship between health care costs in the 6 months prior to the study and those during the 6-to 12-month period after initial randomization. The study thus focused on the sequential relationship between baseline variables (including random assignment to clozapine) and 6-month health status, and between 6-month health status measures and 6-to 12-month measures of costs, controlling for other pertinent effects.
The significance of differences between treatment groups in provider and patient assessments of treatment outcomes were evaluated using / tests for continuous variables and chi-squares for categorical measures.
Data on average medication dosages and pharmacy costs were derived from VA prescription data bases using methods described elsewhere Rosenheck 2001a, 2001Z?) and from the Marketscan® data base, a compendium of clinical and pharmacy claims from corporation-sponsored health plans (Leslie and Rosenheck 1999) . Further data on commercial medication prices were obtained from published sources {Drug Topics Red Book 1999) and websites (Drugstore.com, Walgreens.com).
Structural equation models were evaluated using the CALIS procedure in SAS software (SAS Institute 1990). All analyses used an alpha value of 0.05 as the criterion for statistical significance.
Results
Demographic and Clinical Variables. A comparison of sociodemographic and clinical characteristics between patients with complete data and patients with incomplete data showed no significant differences (data available on request). Comparison of patients for whom complete data were available who were assigned to either clozapine or haloperidol showed only one significant difference: Patients assigned to clozapine had a higher lifetime history of alcohol abuse (table 1) .
Clinical and Cost Outcomes. Six-month clinical outcomes assessed with standard measures (n = 317) showed significantly lower symptoms and side effects, and higher ratings of social functioning among patients assigned to clozapine (table 2) . Furthermore, between 6 and 12 months, patients randomly assigned to clozapine had significantly lower inpatient costs, higher outpatient costs, and lower non-health care costs, but only marginally lower total health and societal costs (p < 0.10) (table 2).
Structural Equation Models
. The six structural equation models of the relationship of clinical status and costs all had goodness-of-fit indexes greater than 0.91, with parsimony indexes ranging from 0.33 to 0.34.
Not surprisingly, among the strongest predictors of 6-month clinical status and 6-to 12-month costs in all models were the corresponding baseline measures (figures 1 and 2). Clozapine was also found in these models to be negatively associated with 6-month symptomatology and side effects, and positively associated with social functioning.
Structural equation models of inpatient (figure 1) and outpatient (figure 2) costs identified significant clinical factors that appear to mediate the relationship between assignment to clozapine and these specific cost components. Assignment to clozapine was negatively associated with inpatient costs, a relationship that was mediated solely by the drug's influence on social functioning (figure 1). In contrast, clozapine treatment was associated with increased outpatient costs, both directly, most likely reflecting greater drug costs and the requirement for white blood cell monitoring visits, and indirectly, as mediated by both reduced symptomatology and improved social functioning. It appears, at first, paradoxical that these improvements in clinical outcomes were associated with increased outpatient costs. However, the observed associations may reflect the greater availability and relevance of outpatient treatment for these patients because they spent fewer days in the hospital and may have had greater capacity for and interest in participating in psychosocial rehabilitation. An 
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additional structural equation model evaluated an additional pathway from assignment to clozapine to the use of psychosocial rehabilitation services and from use of psychosocial rehabilitation services to increased costs and found both paths to be highly significant ( figure 3 ). Once use of these services was included in the model, the pathways from symptoms and social functioning to increased outpatient costs were no longer significant, suggesting that their effects on costs were mediated through use of psychosocial services. These findings are consistent with the hypothesis that the relationship of clinical improvement to increased outpatient costs is mediated through the use of psychosocial rehabilitation services. As with the t tests, structural equation models failed to show any association between clozapine and total health care, non-health care, or societal costs, either directly or indirectly (data available on request).
Provider and Patient Assessments of Effectiveness.
Consistent with the standardized rater assessments of symptoms and social functioning, providers' judgments at 6 months suggest that patients assigned to clozapine had shown greater improvement since entering the study than controls (table 2) and were more likely to have shown dramatic improvement by the end of the study.
On the global subjective quality of life assessment, patients assigned to clozapine rated themselves no higher than controls; in addition, there were no differences in their personal assessments of medication effectiveness on four of five measures (table 2) . However, 7 percent more clozapine patients reported that their medication helped them, although there was no significant difference on the overall subjective medication effectiveness index.
Consistent with standardized rating scales, patients assigned to clozapine were less likely to report EPS or akathisia. However, they were more likely to report each of the other side effects and reported a greater total number of side effects overall (table 2) . Patients assigned to clozapine were more likely than others to attribute their side effects to their medication, but there was no difference between groups in the severity of reported side effects. To summarize these results, we created an index in which each side effect was weighted for its severity. Patients assigned to clozapine scored significantly higher on this index (table 2) .
There was no significant difference between the groups in patient reports of compliance.
Medication Costs. In 1993, at the time of the original trial, clozapine costs to the VA averaged $2.10 per 100 mg, which, apart from the costs of weekly white blood cell monitoring, results in total annual costs of $4,545 for an uninterrupted year of treatment, using VA data on the average dose of clozapine in the year 2000 (Rosenheck et al. 1997; table 3) . Table 3 shows a range of estimated medication dosages and estimated annual medication costs for fiscal year (FY) 2000. Within the VA system in FY 2001, clozapine costs were only $3,016, while annualized risperidone costs were as low as $1,254, at the average national dosage level. Dosages in the Marketscan data base, a compilation of private sector claims (Leslie and Rosenheck 1999 ) that included 1,082 people diagnosed with schizophrenia in the year 2000, showed average dosages similar to, but somewhat lower than, those observed in the VA. Costs for atypicals, nevertheless, were somewhat higher than in the VA, ranging from $2,367 annually for risperidone to $3,551 for clozapine.
Wholesale and retail drug prices estimated from the Drug Topics Red Book (1999) and from two online discount vendors, Walgreens.com and Drugstore.com, showed that the annual cost for atypicals ranged from $2,221 for risperidone at the Red Book wholesale price to $8,147 for clozapine if purchased from Walgreens. While clozapine is consistently the most expensive medication, and risperidone the least expensive, prices vary by as much as several thousand dollars across health care systems and vendors.
Discussion
This study examined three ways in which the environment and perspectives within which the cost-effectiveness of new antipsychotic medications are evaluated have become more diverse and complex in recent years. The first generation of controlled trials that evaluated the cost-effectiveness of newer antipsychotic medications (1) were conducted with clinical samples in which the vast majority of total expenses were for the cost of inpatient care, (2) measured effectiveness using standardized clinical tools that addressed outcomes from the perspective of researchers, and (3) assumed that the medications under study had a single uniform price. Under these conditions, it appeared that the first atypical antipsychotic, clozapine, reduced symptoms and side effects as compared with conventional medications and saved enough on inpatient costs to offset the substantially greater cost of the medications, at least in high-cost patients.
In this study, we reanalyzed data from one of those early trials and confirmed previous findings that 6 months after randomization, clozapine has a beneficial effect on the symptoms of schizophrenia, on social functioning, and on EPS, as measured by standard instruments. Structural equation models suggested that the effect of clozapine on social functioning (although not symptoms or EPS) mediates its effect of reducing inpatient health care costs. By contrast, clozapine treatment was associated with greater 6-to 12-month outpatient costs, both directly (the strongest predictor) and, indirectly and paradoxically, via reduced symptomatology and increased social functioning. The direct effect of clozapine on outpatient costs is no doubt attributable to higher drug costs and more frequent visits required for white blood cell monitoring, both of which increase outpatient costs independent of any treatment effects. The indirect effect of symptom reduction and functional improvement on outpatient costs suggests that as severely ill patients spend less time in the hospital, they have a greater amount of time in the community in which they can utilize outpatient services and a greater capacity to participate in rehabilitation activities. An additional structural equation model that included the pathway from clozapine through psychosocial rehabilitation to outpatient costs was consistent with this interpretation.
Other planned structural equation models failed to show any relationship between clozapine assignment and total health care, non-health care, or societal costs, most likely because decreased inpatient costs were offset by increased outpatient and drug costs, and because non-health care costs were not mediated by clinical measures.
Although these analyses may pertain to only the most seriously Ul patients, they are particularly relevant to future cost-effectiveness studies of antipsychotic medication because, as inpatient treatment becomes a less predominant aspect of the treatment of schizophrenia and psychosocial rehabilitation initiatives expand, newer, more effective medications may be found to increase, rather than decrease, health care costs, at least in more severely ill patients.
We were also surprised to find that, whereas clinician ratings of improvement were consistent with standard psychometric measures, patient-based assessments were not As reported previously, there were no differences between groups on global ratings of subjective quality of life (Cramer et al. 2000) , but on a series of supplemental questions patients treated with clozapine had no more positive view of their medication than controls on most measures and reported a greater number of equally severe side effects. It is notable that the side effects that have received the greatest emphasis in evaluations of atypical antipsychotics have been EPS, on which atypical antipsychotics are clearly preferable to conventional agents. However, consideration of a wider range of side effects and patient-rated assessment of both their relationship to the current medication and their severity suggests that the side effect profile of clozapine may be less acceptable than that of conventional medications, on the whole, at least from the patient perspective.
Finally, while the measurement of drug costs in the 1993-1996 VA study appeared simple and straightforward, circumstances have become considerably more complex since then. The VA has negotiated substantial discounts with drug companies (U.S. GAO 2000) so that the prices it pays are lower than those found elsewhere, but substantial differences were also observed between annualized medication costs observed in a sample of patients treated in the private sector and related costs estimated from published price lists of major vendors. Future cost-effectiveness analyses will need to be based on sensitivity analysis using a range of possible medication prices.
Potential Limitations. Several methodological limitations of this study require comment. The inclusion of patients who were refractory to typical antipsychotic agents (i.e., who had failed previous trials of haloperidol), but not ones who had failed a previous trial of clozapine, may have biased the findings in favor of clozapine, a bias that was practically unavoidable at the time of this study because of the widespread previous exposure to haloperidol.
Second, these analyses were conducted on the original, unbiased intention-to-treat randomized sample. It is inevitable that in a long-term trial, as in clinical practice, not all patients adhere to a treatment protocol, and hence crossovers occur. As a result, the observed associations must be considered conservative estimates; they might have been stronger had there been complete followup data and adherence to the treatment protocol. Analysis of the data presented here with crossovers excluded did not alter the principal findings.
Third, it must be acknowledged that structural equation modeling does not demonstrate causality but rather shows sequential correlations that are consistent with pos-tulated causal effects. Hence, while one may infer from these models that clozapine causes an increase in 6-to 12-month outpatient costs both directly and through its beneficial effect on symptoms and social functioning, only an association between the variables was demonstrated. However, the temporal ordering of the associations is consistent with a causal process.
Fourth, the generalizability of these findings is uncertain for two reasons. First, since these study data were collected, the U.S. Food and Drug Administration has adjusted the schedule of required blood draws for clozapine-treated individuals to once every 2 weeks after the first 6 months of treatment, rather than once per week, thus lowering both the direct, if modest, cost of blood draws and, to an unknown extent, the number of additional outpatient visits associated with frequent visits to the hospital. Furthermore, the patients involved in this study were all treated in the VA system. Patients in the VA system tend to be more often male, to be older, to be of lower socioeconomic status, and to have spent more time in the hospital than those treated in other health care systems. The generalizability of our findings to other health care systems is thus unknown.
Conclusion. This study presented evidence suggesting that while the improved social functioning associated with clozapine treatment appears to mediate the lowering of inpatient costs, both improved functioning and reduced symptoms are associated with increased outpatient costs, even after the direct effects of clozapine on increased outpatient costs are independently modeled. It is thus possible that as the emphasis in schizophrenia treatment shifts from inpatient to outpatient and rehabilitative care, more effective medications may be associated with increased rather than decreased nondrug clinical costs. Further, the study suggested that even when standard instruments and clinician judgment indicate that newer treatments are more effective than standard treatments, subjective patient responses may show no effect or even a negative effect.
Finally, data were presented to show that medication prices vary substantially, not only between different agents but also across treatment systems and vendors, and that there is no single medication price that applies in all circumstances. The cost-effectiveness of new treatments, such as those that will be evaluated in studies like CA'l'lH, will increasingly need to be tied to the specific characteristics of mental health service systems, evaluation perspectives, and drug cost schedules.
